Cheviot Value Management LLC Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Cheviot Value Management LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 498,740 shares of the biopharmaceutical company's stock after acquiring an additional 58,118 shares during the period. Pfizer accounts for about 1.5% of Cheviot Value Management LLC's holdings, making the stock its 23rd biggest position. Cheviot Value Management LLC's holdings in Pfizer were worth $11,905,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. William B. Walkup & Associates Inc. raised its position in shares of Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after buying an additional 454 shares during the last quarter. Members Trust Co raised its position in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC raised its position in shares of Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after buying an additional 472 shares during the last quarter. Bellevue Group AG raised its position in shares of Pfizer by 0.3% during the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock valued at $3,756,000 after buying an additional 485 shares during the last quarter. Finally, Gould Capital LLC raised its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PFE. BMO Capital Markets reduced their price objective on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Redburn Atlantic reduced their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. HSBC reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Finally, Leerink Partners reduced their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $28.28.

Pfizer Stock Up 0.9%

Shares of PFE opened at $23.49 on Friday. The firm has a market capitalization of $133.55 billion, a P/E ratio of 17.02, a P/E/G ratio of 0.85 and a beta of 0.52. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.32. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a fifty day moving average price of $24.36 and a 200-day moving average price of $24.57.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.3%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.